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Introduction
AML is a highly heterogeneous disease and despite tremendous progress in understanding and treating this disorder has been made within the last decades, only a minor proportion of patients will be ultimately cured by conventional therapeutic approaches (1, 2) . AlloSCT is the most effective treatment option for AML and, therefore, has become standard of care for the majority of medically fit patients with non-favorable risk disease if a human leukocyte antigen (HLA)-compatible donor is available (2) (3) (4) . Nonetheless, as compared to conventional post-remission therapy, alloSCT is associated with a considerable risk of NRM, which may outweigh the potential survival advantage.
In addition to patient-related variables such as comorbidities or physical performance, risk assessment in AML primarily includes pre-treatment disease-specific factors, e.g. genetic features, initial leukemic cell burden, preceding hematologic disorders such as myelodysplastic syndrome (MDS) or chronic myeloproliferative neoplasia (MPN), or a history of chemo-or radiation therapy. In addition, response to treatment was shown to predict outcome. As such, the rapid achievement of remission by induction therapy has long been recognized as a prognosticator for overall outcome (5-7). Likewise, early blast clearance, as determined one week after the first course of induction chemotherapy, predicts CR rate and has major prognostic relevance irrespective of the type of post-remission therapy (8) (9) (10) (11) . However, the impact of achieving early remission, i.e. absence of leukemic blasts in the bone marrow at the end of the first course of induction therapy, versus delayed remission on the outcome of patients with AML undergoing alloSCT has not yet been specifically explored. We therefore addressed this question in cohort of 132 consecutive patients with AML and an intermediate cytogenetic risk profile transplanted in CR1 at our center between 1994 and 2013.
neutrophil counts reached 1 x 10 9 /l. In patients with a platelet count of ≥50 x 10 9 /l prophylactic cotrimoxazole was started at day +28 following alloSCT. Polyvalent immunoglobulins were administered bi-weekly until day +90 in patients with a total IgG below 5 g/l (14) .
Statistical analyses
Statistical analyses were performed using NCSS 2007 (NCSS; Kayville, UT, USA) and SPSS 14 (SPSS; Chicago, IL, USA) as of September 30 th , 2013. Fisher's exact test and χ 2 test were used for comparing categorical data. Survival data (OS and DFS) were calculated according to Kaplan-Meier and tested univariately by log-rank test. Statistical significance was assessed at the p<0.05 level (two-sided). NRM and relapse are given as cumulative incidences calculated in a competing-risks setting (17). Cox proportional hazard regression model was used for univariate and multivariate analyses and included the following variables: AML subtype, age group, era of alloSCT, interval from diagnosis to alloSCT, extramedullary disease, Karnofsky performance status (KPS), type of conditioning, donor type/HLA-match, and stem cell source. First, a univariate model was calculated for all parameters. Thereafter, forward and backward selection (inclusion p=0.05, exclusion p=0.10) was applied. By definition, the lowest risk category within a group was assigned a hazard ratio (HR) of 1 and used as a reference. HRs are given with a 95% confidence interval (CI) and corresponding pvalues are shown.
Results
Overall outcome
After a median follow-up of 56 (4-220) months for the surviving patients, 87 patients (66%) are alive and in CR. A relapse occurred in 26 patients (20%) after a median interval of 8 (1-133) months, whereas 19 patients (14%) died from NRM. 47 patients (36%) had no aGvHD, whereas 27 (20%) or 58 patients (44%) developed °I or °II-IV aGvHD. Chronic GvHD was absent in 65 patients (49%) and limited or extensive chronic cGvHD occurred in 40 (30%) or 27 patients (21%). Projected OS (95% CI) or DFS (95% CI) of the entire cohort after 1, 3, 5, and 10 years was 81% (74-88%), 68% (59-75%), 65% (56-74%), and 61% (49-73%) or 75% (67-83%), 68% (59-76%), 65% (56-74%), and 59% (47-71%). At the same time points the cumulative incidence of relapse (CI-R) (95% CI) or non-relapse mortality (CI-NRM) (95% CI) was 12% (8-20%), 19% (13-28%), 22% (15-32%), and 22% (15-32%) or 13% (8-20%), 13% (8-20%), 13% (8-20%), and 17% (10-31%).
Outcome according to remission status after the first course of induction therapy
We next analyzed OS, DFS, CI-R, and CI-NRM according to the remission status after the first course of induction therapy. Specifically, 79 patients (60%) achieved ER defined as bone marrow blast <5% at day +16 after the first course of induction therapy, whereas 53 patients (40%) had a DR, i.e. first hematologic remission was achieved after two cycles of induction therapy. As shown in Table 1 , there were no statistically significant differences with regards to gender, age group, AML subtype, transplant era, extramedullary disease, time from diagnosis to transplantation, KPS, donor type/HLA-match, conditioning regimen, or stem cell source between the ER and the DR subgroup. As displayed in Figure 1 , patients who achieved ER had a significantly higher OS as compared to patients displaying DR (p=0.0313). Likewise, ER predicted a significantly lower relapse incidence CI-R (p=0.004). No statistically significant differences in CI-NRM between the two subgroups were found (p=0.638).
Uni-and multivariate analysis
To further analyze the prognostic impact of ER versus DR we performed univariate analyses by using the Cox proportional hazard regression model. In addition to remission status, a number of other factors were analyzed in parallel. As shown in Table 2 , DR was associated with an inferior OS and DFS as well as an increased relapse rate. Similarly, a KPS of ≤80% was predictive of a lower OS and DFS. Specifically, patients with a KPS of ≤80% had a higher risk of relapse, whereas the CI-NRM was not elevated as compared to patients with a KPS >80%. Patients transplanted from a mismatched unrelated donor (mMUD) had an inferior OS and DFS as compared to patients with a matched related or unrelated donor. Furthermore, patients with AML evolving from MPN or MDS as well as patients with therapy-related AML (tAML) had an inferior survival as compared to patients with de novo AML. All other factors examined were not predictive for OS, DFS, CI-R, or CI-NRM. Next, multivariate analysis was performed. As shown in Table 3 , DR was associated with a significantly lower DFS and a higher CI-R. A KPS of ≤80% was an independent prognosticator for a lower OS. None of the factors examined was predictive for NRM (data not shown).
Outcome according to type of conditioning
Finally, we analyzed whether the type of conditioning therapy impacts on overall outcome and relapse incidence in patients achieving ER as compared to patients displaying DR ( Table  4) . Neither in the ER nor in the DR subgroup a statistically significant difference in OS, DFS, or CI-R between patients treated with MAC or RIC was found. In particular, relapse risk was not elevated in patients displaying DR undergoing RIC-alloSCT.
Discussion
The analysis of 132 consecutive patients with AML and an intermediate cytogenetic risk profile who underwent alloSCT in CR1 at our center suggests, that achieving ER as compared to DR is associated with a favorable overall outcome. Importantly, we demonstrate that the beneficial effect of ER versus DR with regards to DFS and relapse incidence is maintained in multivariate analysis, which suggests that it has independent prognostic value. Furthermore, achieving ER strongly correlates with early blast clearance, which was shown before to be predictive for overall outcome of patients with AML irrespective of the type of post-remission therapy (8) (9) (10) (11) . In general, our data underline the importance of treatment response for generating an integrated risk-profile which, therefore, should be incorporated into a decision algorithm for patients with AML as has been proposed recently by the European Leukemia Network (3). Furthermore, our data implicate that the adverse effect of failure to achieve ER is not fully overcome by alloSCT even in patients entering CR after a consecutive course of induction therapy. A recent analysis reported by the ECOG suggests that patients entering remission after one or two cycles of induction have a similar prognosis (18). However, this cohort was heterogeneous with respect to cytogenetic risk group and type of post-remission therapy, i.e. transplant versus conventional therapy, which may explain the discrepancy. Patients reaching ER are characterized by a remarkably low relapse incidence, which is in the range of 10-15% at 10 years after alloSCT. Likewise, NRM levels off around 10-15% as early as 18 months post-transplant and remains stable thereafter. In principle, these results underline that alloSCT is not only feasible in this setting, but highly effective and safe. Consequently, alloSCT should be considered as first choice post-remission treatment option for medically fit patients with intermediate-risk AML entering CR1 if an HLA-compatible donor is available. In this regard, our results are in line with a number of recently published studies reporting data from donor-versus-no donor comparisons, matched pair analyses, and randomized phase-III multicenter clinical trials (3, (19) (20) (21) (22) . Nonetheless, it might be of interest to address whether the speed of achieving remission, i.e. ER versus DR, is of prognostic relevance in other genetic risk groups of AML patients undergoing alloSCT in CR1 as well. In contrast, both OS and DFS are significantly reduced in patients showing DR albeit CR1 was reached after a second induction cycle is administered. This is due to a considerably higher relapse incidence reaching a plateau of close to 40% at five years after alloSCT. It is obvious to assume that occult populations of leukemic cells outlasting two or more courses of induction/consolidation therapy are the primary source of disease recurrence in this situation. Indeed, two recently published analyses using pre-transplant minimal residual disease (MRD) monitoring suggest that even minute populations of residual leukemic cells, e.g. below <0.1% as detected by multicolor flow-cytometry, in patients achieving morphologic CR prior to alloSCT give rise to relapse and, thereby, have a tremendous impact on overall outcome (23, 24). Specifically, 3-year OS declines to around 30% in MRD-positive patients as compared to 75% in patients MRD-negative pre-transplant. In our cohort, data pre-transplant MRD were available in only 53/132 patients. In the subgroup of MRD-negative patients (N=33) 4 relapses occurred, whereas in 8/20 MRD-positive patients relapsed after alloSCT (p=0.007). However, due to the limited number of patients in each subgroup we are unable to interpret pre-transplant MRD in the context of ER versus DR. Nonetheless, this inevitably brings up the question how to tackle the dilemma of failure to achieve an early and/or molecular CR before proceeding to alloSCT. One approach could be to apply repetitive courses of consolidation chemotherapy until MRD negativity is reached. A recently published analysis of EBMT registry data clearly indicates that, at least for patients with AML undergoing RICalloSCT in CR1, consolidation therapy neither reduces the risk of relapse, nor improves overall outcome (25). One should assume that the results in patients undergoing alloSCT following MAC are similar. Alternatively, risk-adapted post-transplant management, e.g. early cessation of immunosuppressive therapy and/or the use adoptive immunotherapy to fully exploit the beneficial graft-versus-leukemia (GvL) effect might serve to overcome the risk of therapeutic failure in this situation (26-28). This strategy is supported by the observation that the occurrence of GvHD reduces the risk of disease recurrence irrespective of the presence or absence or MRD (24). Furthermore, novel therapeutics such as hypomethylating agents might be used to prevent relapse by enhancing the GvL effect (29, 30). In any event, despite the higher relapse risk in patients who, in addition of being in hematologic remission, do not meet more stringent response criteria, e.g. MRD negativity, after two courses of induction chemotherapy, alloSCT should not be withheld, because the results with conventional post-remission therapy is dismal. In patients showing delayed remission during induction therapy, intensive conditioning such as a myeloablative approach might be compensatory by effectively eradicating residual leukemic cells in the recipient prior to allografting. Therefore, we analyzed overall outcome and relapse incidence according to the type of conditioning in both the ER and the DR subgroup. However, we failed to reveal any significant differences between patients treated with either MAC or RIC prior to alloSCT. Specifically, OS and relapse incidence were not lowered by MAC as compared to RIC in the DR group. Yet, the number of patients in each subgroup is small and, therefore, data must be interpreted with due caution. Analyzing larger data sets should allow for answering this important question. Despite the limitations of a retrospective analysis in a rather small cohort of patients, our data indicate that achieving early remission by induction therapy is an independent predictor for overall outcome in patients with AML and an intermediate risk karyotype transplanted in CR1. In turn, delayed remission is associated with an adverse outcome and, therefore, should prompt for maneuvers to counteract the high risk of disease recurrence. In addition to transplantion-specific options, e.g. rapid tapering of immunosuppression and the administration of donor lymphocyte infusions (DLI), these may also include the use of novel therapeutics including hypomethylating agents or, when applicable, mulitkinase inhibitors, e.g. in FLT3-ITD positive AML, in the post-transplant setting (31, 32). Furthermore, innovative strategies to detect and treat an impeding relapse after transplant as early as possible are clearly warranted in the future. Table 4 : Outcome according to type of conditioning in ER versus DR patients. Univariate analysis was performed by using the Cox proportional hazard regression model in the ER and the DR subgroup of patients treated with either RIC or MAC prior to alloSCT.
Figure 1: Outcome of alloSCT in patients achieving early remission (ER) versus delayed remission (DR).
Overall survival (OS), cumulative incidence of relapse (CI-R) and non-relapse mortality (CI-NRM) were analyzed by Kaplan-Meier (OS) or calculated in a competing risk setting (CI-R, CI-NRM). In patients achieving early remission (ER) OS and CI-R is significantly better as compared to patients with delayed remission (DR), whereas no significant difference in NRM between the subgroups was found.
